- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Pozelimab + Cemdisiran, Cemdisiran, Placebo, Pozelimab
- Drug · Other
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Myasthaenia Gravis
- Interventions
- Decartes-08, Placebo Drug
- Biological · Other
- Lead sponsor
- Cartesian Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Carlsbad, California • Los Angeles, California + 19 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Orange, California • San Francisco, California • Miami, Florida + 9 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Denton, Texas
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- M281
- Drug
- Lead sponsor
- Momenta Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 20 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Whole-body Electrical Muscle Stimulation Exercise
- Device
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Columbia, Missouri
- Conditions
- Myasthenia Gravis
- Interventions
- eculizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Orange, California • Sacramento, California + 17 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Rozanolixizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more
- Conditions
- Myasthenia Gravis, Generalized Myasthenia Gravis
- Interventions
- Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101
- Drug · Biological
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 7 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Zilucoplan
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Gefurulimab
- Combination Product
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Norfolk, Virginia
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- Iptacopan, Matching Placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Fullerton, California • Pasadena, California + 18 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- zilucoplan (RA101495), Placebo
- Drug
- Lead sponsor
- Ra Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
- Conditions
- Myasthenia Gravis
- Interventions
- IM-101 Part A, Placebo Part A, IM-101 Part B, Placebo Part B
- Drug
- Lead sponsor
- ImmunAbs Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Altamonte Springs, Florida • Boca Raton, Florida • Naples, Florida + 4 more
- Conditions
- Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Myasthenia Gravis, Muscle Weakness
- Interventions
- anito-cel, Standard Lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Arcellx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 10 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 13
- States / cities
- Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more
- Conditions
- Generalized Myasthenia Gravis, Myasthenia Gravis
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
- Conditions
- Generalized Myasthenia Gravis, gMG
- Interventions
- Efgartigimod IV or Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia
- Conditions
- Myasthenia Gravis
- Interventions
- TAK-079, TAK-079 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- ARGX-113
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Carlsbad, California • Los Angeles, California • Orange, California + 11 more
- Conditions
- Myasthaenia Gravis
- Interventions
- Belimumab, Placebo
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 12 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Claseprubart, Placebo
- Drug
- Lead sponsor
- Dianthus Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
- Conditions
- Myasthenia Gravis
- Interventions
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Drug
- Lead sponsor
- Muscular Dystrophy Association
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
- Interventions
- Not listed
- Lead sponsor
- Brain Inflammation Collaborative
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Delafield, Wisconsin